TopFunds

West Pharmaceutical Services

NYSE: WST

Stock price

363.27 USD

(-10.78%) 5 years

Health Care SuppliesMedical - Instruments & Supplies

Financial Performance

Share

5Y price score: (14)

Help

The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.

A score of 100 indicates that the stock did as well as the S&P 500 Index.

A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.

10Y return: 390.4%

DATE RANGE:

%

ㅤ

  • Earnings per share

  • Free cash flow per share

  • Stock price

Time scale:

By default your notes are visible only to you.

223.8

52-week range

386.0

363.27

Your model inputs

Required return / cost of capital
%
FCFF terminal growth rate
%

Your fair value & Margin of safety

To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.

Forecast:

Valuation

Free Cash Flow Yield

Help
FCF Yield TTM = Trailing Twelve Months free cash flow per share / current market price per shareLearn more

1.7 %

Dividend Yield TTM

0.2 %

Market cap $

$ 25,565

Price / Earnings TTM

Help
P/E TTM = current market price per share / Trailing Twelve Months diluted earnings per shareLearn more

46.5

Price / Book TTM

8.6

PEG TTM

Help
Price/Earnings-to-Growth ratio = P/E TTM divided by most recent annual diluted earnings per share growth rateLearn more

28.3

Earnings growth and return

LTM

5YR

10YR

Total return (price & dividends)

35.9 %

(9.8) %

390.4 %

Free cash flow per share growth

(19) %

64 %

489.1 %

Earnings per share growth

18.1 %

48.8 %

423.1 %

Founded: 1,923

Employees: 10,600

Business Summary:West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.

Q&A

SEARCH
Get answers on financials, industry, fundamentals or other questions.

Contribute

By providing well-researched and detailed answer you increase your chance of becoming Top Contributor. TopFunds is free for all top contributors. Learn more

VIEW ALL Q&A

Contribute or ask questions about business following TopFunds community guidelines

Fair Value Reference Estimate

Latest Earnings Call Takeaways

2026 Q2 (Jul 23, 2026)

1) Strong Financial Performance
- Revenues for Q2 2026 reached $872 million, a 13% organic growth YoY.
- Adjusted EPS was $2.37, reflecting a 29% increase compared to the previous year.
- Proprietary Products segment grew 15.5% organically, with HVP Components driving 18.4% growth.
- The company raised its full-year guidance, now expecting organic revenue growth of 10% to 11% and adjusted EPS between $8.85 to $9.05.

2) Segment Highlights and Growth Drivers
- Proprietary Products: Continued strong performance, particularly in Biologics and Biosimilars, with 29% growth in the Biologics market.
- HVP Components: Now accounts for 49% of total revenues, driven by GLP-1s and HVP upgrades.
- Standard Products: Slight growth of 0.7%, serving as a funnel for future upgrades to HVP Components.
- HVP Delivery Devices: Grew 29% organically, with strong demand for SmartDose and other devices.

3) Operational Challenges and Cyber Incident Recovery
- The company faced challenges due to a cyber incident in May, impacting the West Vantage segment, which grew only 0.8% organically.
- The incident resulted in a mid-single-digit impact on growth, but recovery efforts were noted as successful, contributing to overall strong Q2 results.
- Operational excellence initiatives helped mitigate the impact of the cyber incident.

4) Guidance and Future Outlook
- Full-year revenue guidance increased to $3.345 billion to $3.380 billion, with reported growth now projected at 8.8% to 10%.
- Q3 revenue guidance is set between $820 million to $835 million, reflecting a 1.9% to 3.8% increase.
- Continued strong growth expected in GLP-1s and non-GLP-1 HVP Components, with both anticipated to grow in the high teens.
- Margin expansion of over 200 basis points is expected for the year, despite inflationary pressures.

5) Leadership Transition and Strategic Focus
- Eric Green will transition leadership to Michel Lagarde on August 31, marking a significant change in the company's direction.
- The company remains focused on its three key growth drivers: Biologics, GLP-1s, and Annex 1 upgrades.
- Further details on the impact of leadership change and long-term strategic initiatives were not fully covered in the call.

Bottom line: West Pharmaceutical Services demonstrated robust financial performance in Q2 2026, driven by strong growth in proprietary products and strategic initiatives. The company is well-positioned to capitalize on long-term trends in the Biologics and GLP-1 markets, despite operational challenges from a recent cyber incident. The leadership transition may bring new perspectives, but the existing growth strategy remains intact, making it a favorable outlook for shareholders.

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
2025202420232022202120202019201820172016

West Pharmaceutical Services — Financial Overview, Stock Price, Market Cap

West Pharmaceutical Services is a company. Founded in 1923. As of October 9, 2026, the company's market capitalization is $25565416866 with a current stock price of $363.27.